Trial · NCT00167310
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
NCT00167310, Phase 2, Completed, University of Pittsburgh; results first posted 2017-04-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation. Trials, record NCT00167310. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00167310
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
- NCT number
- NCT00167310
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
- Interventions
- Eicosapentaenoic acid (omega-3 fatty acid), Placebo
- First posted
- 2005-09-14
- Last updated
- 2017-04-10
- Results first posted
- 2017-04-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Levels of Triglycerides and Lipoprotein Cholesterol | 4 months | Biochemical measures: Plasma levels of triglycerides, small dense LDL (LDL3- and LDL4-) cholesterol, large buoyant LDL (LDL1- and LDL2-) cholesterol, and HDL2-cholesterol. |
| Secondary | Plasma Cholesterol Levels in Various Lipoprotein Fractions | 4 months | Biochemical Measures: Plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, Lp(a) cholesterol, IDL-cholesterol, HDL3-cholesterol, VLDL1,2-cholesterol, and VLDL3-cholesterol. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Plasma Levels of Triglycerides and Lipoprotein Cholesterol | 4 months | Plasma triglyceride levels | mg/dL | MEAN |
| SECONDARY | Plasma Cholesterol Levels in Various Lipoprotein Fractions | 4 months | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Omega-3 Fatty Acid | Plasma triglyceride | 155 | Standard Deviation 78 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Placebo | Plasma triglyceride | 182 | Standard Deviation 67 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Omega-3 Fatty Acid | Plasma LDL-1 cholesterol | 12.68 | Standard Deviation 4.93 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Placebo | Plasma LDL-1 cholesterol | 16.92 | Standard Deviation 7.10 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Omega-3 Fatty Acid | Plasma LDL-2 cholesterol | 14.62 | Standard Deviation 11.36 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Placebo | Plasma LDL-2 cholesterol | 15.79 | Standard Deviation 12.37 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Omega-3 Fatty Acid | Plasma LDL-3 cholesterol | 40.93 | Standard Deviation 14.69 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Placebo | Plasma LDL-3 cholesterol | 43.47 | Standard Deviation 23.44 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Omega-3 Fatty Acid | Plasma LDL-4 cholesterol | 15.61 | Standard Deviation 10.47 | mg/dL |
| Plasma Levels of Triglycerides and Lipoprotein Cholesterol | Placebo | Plasma LDL-4 cholesterol | 17.66 | Standard Deviation 12.50 | mg/dL |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Omega-3 Fatty Acid | 29 | |
| Overall Study | STARTED | Placebo | 28 | |
| Overall Study | COMPLETED | Omega-3 Fatty Acid | 21 | |
| Overall Study | COMPLETED | Placebo | 18 | |
| Overall Study | NOT COMPLETED | Omega-3 Fatty Acid | 8 | |
| Overall Study | NOT COMPLETED | Placebo | 10 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | EKG report indicated sinus bradycardia with HR of 39. Patient asymptomatic. | Cardiac disorders | Omega-3 Fatty Acid | 1 | 28 | 1 |
| other | EKG report indicated sinus bradycardia with HR of 39. Patient asymptomatic. | Cardiac disorders | Placebo | 0 | 24 | 0 |
| other | Patient experiences mental problem | Psychiatric disorders | Omega-3 Fatty Acid | 1 | 28 | 1 |
| other | Patient experiences mental problem | Psychiatric disorders | Placebo | 1 | 24 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Omega-3 Fatty Acid | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Omega-3 Fatty Acid | 2 | 28 |
| Total, other adverse events | Placebo | 1 | 24 |
| Total, serious adverse events | Omega-3 Fatty Acid | 0 | 28 |
| Total, serious adverse events | Placebo | 0 | 24 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34817851 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Omega-3 Fatty Acid vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00167310
GET https://conductscience.org/api/trials/v1/NCT00167310/results?page=2